Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Xilio Development Inc (XLO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: XLO (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $4
1 Year Target Price $4
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -21.68% | Avg. Invested days 28 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 36.39M USD | Price to earnings Ratio - | 1Y Target Price 4 |
Price to earnings Ratio - | 1Y Target Price 4 | ||
Volume (30-day avg) 1 | Beta -0.12 | 52 Weeks Range 0.61 - 1.70 | Updated Date 08/15/2025 |
52 Weeks Range 0.61 - 1.70 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.65 |
Earnings Date
Report Date 2025-08-14 | When - | Estimate -0.1 | Actual -0.16 |
Profitability
Profit Margin - | Operating Margin (TTM) -472.73% |
Management Effectiveness
Return on Assets (TTM) -38.21% | Return on Equity (TTM) -297.84% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -44821597 | Price to Sales(TTM) 3.92 |
Enterprise Value -44821597 | Price to Sales(TTM) 3.92 | ||
Enterprise Value to Revenue 1.95 | Enterprise Value to EBITDA -0.11 | Shares Outstanding 51782300 | Shares Floating 24896917 |
Shares Outstanding 51782300 | Shares Floating 24896917 | ||
Percent Insiders 45.76 | Percent Institutions 22.87 |
Upturn AI SWOT
Xilio Development Inc
Company Overview
History and Background
Xilio Development Inc. is a biopharmaceutical company focused on developing tumor-selective immuno-oncology therapies for patients with cancer. Founded in 2016, the company has focused on engineering potent cancer immunotherapies designed to limit activity in healthy tissues.
Core Business Areas
- Immuno-Oncology: Xilio is focused on developing tumor-selective immuno-oncology therapies.
- Drug Development: The company's core business involves research, development, and clinical trials of its novel drug candidates.
Leadership and Structure
The leadership team includes seasoned executives with experience in biotechnology and pharmaceutical development. The organizational structure likely consists of research, clinical development, and business operations departments.
Top Products and Market Share
Key Offerings
- XTX101 (anti-CTLA-4 antibody): A tumor-selective anti-CTLA-4 antibody designed to enhance the therapeutic index of CTLA-4 inhibition. Currently in clinical development. Market share data not yet available as it is not commercialized. Competitors include marketed CTLA-4 inhibitors such as Yervoy (ipilimumab) from Bristol Myers Squibb and other companies developing similar therapies.
- XTX202 (IL-2 variant): A tumor-selective IL-2 variant designed to promote anti-tumor immunity while minimizing systemic toxicity. Currently in clinical development. Market share data not yet available as it is not commercialized. Competitors include high-dose IL-2 therapies and other companies developing IL-2 variants with improved safety profiles.
Market Dynamics
Industry Overview
The immuno-oncology market is a rapidly growing segment of the pharmaceutical industry, driven by the success of checkpoint inhibitors and other immunotherapies. The market is characterized by intense competition and high innovation rates.
Positioning
Xilio is positioned as a company developing next-generation immuno-oncology therapies with improved tumor selectivity and reduced toxicity. Its competitive advantage lies in its tumor-selective technology platform.
Total Addressable Market (TAM)
The global immuno-oncology market is estimated to be in the tens of billions of dollars and is expected to continue to grow. Xilio aims to capture a portion of this market by developing safer and more effective therapies. Exact TAM and market share cannot be determined without current revenue.
Upturn SWOT Analysis
Strengths
- Novel tumor-selective technology platform
- Strong scientific team
- Promising preclinical and clinical data
- Focus on high unmet medical need
Weaknesses
- Limited clinical data
- High cash burn rate
- Reliance on clinical trial success
- Early stage company
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline with new targets
- Positive clinical trial results leading to regulatory approval
- Expansion into new therapeutic areas
Threats
- Clinical trial failures
- Competition from established players
- Regulatory hurdles
- Economic downturn impacting funding
Competitors and Market Share
Key Competitors
- BMY
- MRK
- REGN
Competitive Landscape
Xilio faces intense competition from established pharmaceutical companies and other biotech firms developing immuno-oncology therapies. Its tumor-selective technology platform may offer a competitive advantage, but clinical validation is crucial.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is primarily reflected in the advancement of its pipeline and preclinical development.
Future Projections: Future growth depends on successful clinical trials and potential partnerships.
Recent Initiatives: Recent initiatives include advancing its lead candidates through clinical development and presenting data at scientific conferences.
Summary
Xilio Development Inc. is a promising, yet risky, early-stage biopharmaceutical company focused on tumor-selective immuno-oncology therapies. Its novel technology platform offers a potential competitive advantage. Key strengths include the team and the potential to develop drugs that will lead to less toxic side effects. Significant risk is tied to clinical trial success and potential partnerships as it has no current revenue.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Industry Reports
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The information provided is based on publicly available data and may not be entirely accurate or complete. Market share figures are estimations.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Xilio Development Inc
Exchange NASDAQ | Headquaters Waltham, MA, United States | ||
IPO Launch date 2021-10-22 | President, CEO & Director Dr. Rene Russo BCPS, Pharm.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 64 | Website https://xiliotx.com |
Full time employees 64 | Website https://xiliotx.com | ||
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.